All Releases
 |
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
Mar 2, 2010
|
19.1 KB |
|
| |
FOSTER CITY, CA, Mar 02, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the fourth quarter and year ended December 31, 2009. Revenues for the fourth quarter of 2009 grew to $18.1 million, or 18% compared to the fourth quarter of 2008. Net income for the fourth quarter of 2009 wa...
|
|
SciClone Pharmaceuticals to Present at Three Investor Conferences in March
Mar 1, 2010
|
7.2 KB |
|
| |
FOSTER CITY, CA, Mar 01, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Rodman & Renshaw Annual China Investment Conference, Cowen Healthcare Conference, and Roth Growth Stock Conference. SciClone's executives will present a corp...
|
|
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010
Feb 18, 2010
|
8.7 KB |
|
| |
FOSTER CITY, Calif., Feb 18, 2010 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
plans to report fourth quarter and year-end results for 2009 on Tuesday,
March 2, 2010. SciClone will host a conference call to give a business
and product update and guidance for 2010 at 4:30 pm ET that...
|
|
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
Feb 8, 2010
|
11.8 KB |
|
| |
FOSTER CITY, CA and ROME, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vacci...
|
|
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 2, 2010
|
6.7 KB |
|
| |
FOSTER CITY, CA, Feb 02, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the BIO CEO & Investor Conference 2010 on February 9, 2010 at 1:30 p.m. ET in New York City....
|
|
SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
Jan 12, 2010
|
11.9 KB |
|
| |
FOSTER CITY, CA and ROME, Jan 12, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vacci...
|
|
SciClone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance
Jan 11, 2010
|
8.6 KB |
|
| |
FOSTER CITY, CA, Jan 11, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its full year 2009 sales revenue, 2010 sales revenue guidance and its year-end cash position as follows:
-- For 2009, the company anticipates revenues of approximately $72.4
million (unaudited), a 34% incre...
|
|
SciClone Announces Commencement and Complete Enrollment of Clinical Study Examining ZADAXIN's Ability to Enhance the H1N1 Vaccine Led by European Partner, Sigma-Tau
Nov 30, 2009
|
11.8 KB |
|
| |
FOSTER CITY, CA, Nov 30, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Rome-based development partner Sigma-Tau, S.p.A., has initiated a
pilot study in Italy to evaluate ZADAXIN's® (thymalfasin) ability
to enhance immune response to the MF59 adjuvanted H1N...
|
|
SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
Nov 23, 2009
|
10.4 KB |
|
| |
FOSTER CITY, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
patient enrollment is complete ahead of schedule for its phase 2
trial of SCV-07 -- a small molecule synthetic peptide with
immunomodulating properties -- for the treatment of severe oral
mucositis (OM) in patients with he...
|
|
SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference
Nov 23, 2009
|
6.1 KB |
|
| |
FOSTER CITY, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the upcoming Piper Jaffray Annual Healthcare
Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's
President and Chief Executive Officer, will present a corporate
overview and business update ...
|
|
SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings
Nov 12, 2009
|
10.7 KB |
|
| |
FOSTER CITY, CA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced
presentations of multiple abstracts demonstrating SCV-07's anti-tumor
immunomodulating properties at two upcoming events: Cold Spring
Harbor Laboratory's Harnessing Immunity to Prevent and Treat Disease
meeting; and the America...
|
|
SciClone Reports Financial Results and Provides Commercial and Pipeline Updates for the Third Quarter of 2009
Nov 9, 2009
|
18.1 KB |
|
| |
FOSTER CITY, CA, Nov 09, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported
financial results for the third quarter of 2009. Revenues for the
quarter grew 20% to $17.2 million compared with the same period last
year. SciClone reported net income of $2.1 million or $0.04 per share
on a basic and diluted ...
|
|
SciClone Pharmaceuticals to Present at Two November Investor Conferences
Nov 3, 2009
|
6.4 KB |
|
| |
FOSTER CITY, CA, Nov 03, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at two upcoming investor conferences in New York
City: Merriman Investor Summit, and Lazard Capital Markets 6th Annual
Healthcare Conference. Gary Titus, SciClone's Senior Vice President
and Chief Financial...
|
|
SciClone Announces Corporate Restructuring and Workforce Reduction
Oct 28, 2009
|
8.5 KB |
|
| |
FOSTER CITY, CA, Oct 28, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced a
corporate restructuring that will reduce its U.S.-based workforce by
approximately 17%, primarily in research and development. This
restructuring follows the discontinuation of SciClone's RP101 phase 2
clinical trial annou...
|
|
SciClone Pharmaceuticals to Report Third Quarter 2009 Results on November 9
Oct 26, 2009
|
8.6 KB |
|
| |
FOSTER CITY, Calif., Oct 26, 2009 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2009 results on Monday, November 9. SciClone will host a conference call to give a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., Preside...
|
|
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
Oct 21, 2009
|
11.5 KB |
|
| |
FOSTER CITY, CA, Oct 21, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
enrollment of its first patient at the Atlanta Gastroenterology
Associates in Atlanta, GA, in a phase 2 trial of SCV-07 for the
treatment of hepatitis C (also known as HCV). This multicenter,
multidose, open-label study ...
|
|
Phase 2 Trial of RP101 in Late-Stage Pancreatic Cancer Discontinued
Oct 2, 2009
|
8.7 KB |
|
| |
FOSTER CITY, CA, Oct 02, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the discontinuation of the investigational treatments under its randomized, placebo-controlled, double-blind Phase 2 trial that is evaluating RP101 -- a nucleoside analog known as BvdU -- for the treatment of late-stage pancreat...
|
|
SciClone Pharmaceuticals to Present at Two September Investor Conferences
Sep 9, 2009
|
7.5 KB |
|
| |
FOSTER CITY, CA, Sep 09, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: ThinkEquity's Annual Growth Conference (G6) in San Francisco, and the UBS Global Life Sciences Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President...
|
|
SciClone Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Sep 4, 2009
|
7.2 KB |
|
| |
FOSTER CITY, CA, Sep 04, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business upd...
|
|
SciClone Reports Financial Results and Provides Pipeline Update for the Second Quarter of 2009
Aug 4, 2009
|
20.8 KB |
|
| |
FOSTER CITY, CA, Aug 04, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported
financial results for the second quarter of 2009. Revenues for the
quarter grew 59% to $22.0 million compared with the same period in
2008. SciClone reported net income of $7.3 million or $0.16 per share
on a basic and diluted b...
|
|
|
